Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxcyte Inc PCVX

Healthcare Biotechnology
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation... see more

Recent & Breaking News (NDAQ:PCVX)

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 11, 2024

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 6, 2024

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

GlobeNewswire September 4, 2024

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire September 3, 2024

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

GlobeNewswire September 3, 2024

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

GlobeNewswire September 2, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)

PR Newswire August 26, 2024

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

Vaxcyte Appoints John Furey to Board of Directors

GlobeNewswire July 2, 2024

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 8, 2024

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

GlobeNewswire March 4, 2024

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 27, 2024

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

GlobeNewswire February 15, 2024

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 2, 2024

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

GlobeNewswire February 1, 2024

Vaxcyte Announces Pricing of $750 Million Public Offering

GlobeNewswire January 30, 2024

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 30, 2024

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

GlobeNewswire January 29, 2024

Vaxcyte Appoints Whitney Jones as Chief People Officer

GlobeNewswire January 16, 2024
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested